Glucocorticoids and Relapse and Infection Rates in Anti-Neutrophil Cytoplasmic Antibody Disease
- 1 February 2012
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Clinical Journal of the American Society of Nephrology
- Vol. 7 (2), 240-247
- https://doi.org/10.2215/cjn.05610611
Abstract
The optimal course of glucocorticoid therapy in anti-neutrophil cytoplasmic autoantibody (ANCA) disease is unknown. This cohort study evaluates effects of glucocorticoid therapy duration on patient outcomes and adverse events. This study assessed 147 patients diagnosed between January 1, 2000 and January 1, 2009 who were treated with glucocorticoids and cyclophosphamide. Patients with end stage kidney disease at presentation, treatment resistance, or who had died within 6 months were excluded. Patients were divided into three groups: 0, 5, or >5 mg prednisone daily at 6 months after therapy initiation. The latter two groups were combined for assessment of adverse events. Wilcoxon rank sum, Kruskal-Wallis, or Fisher's exact tests were used for between-group comparisons. Time to relapse was evaluated by the Kaplan-Meier method with log-rank test for comparison. There were no differences between groups in ANCA specificity, serum creatinine, frequency of risk factors for relapse, or length of therapy with immunosuppressants. Length of glucocorticoid therapy had no impact on time to relapse (hazard ratio, 0.69 [95% confidence interval (CI), 0.23-2.02]; 1.01, [95% CI, 0.57-1.81] for the 5-mg and >5-mg groups, respectively), relapse-free survival, end stage kidney disease, or death. Patients receiving glucocorticoids beyond 6 months had significantly higher incidence of infections (0.64 infections per person-year versus 0.39, P<0.0001) and a marginally significant higher frequency of new-onset diabetes mellitus (odds ratio, 2.03; 95% CI, 0.94-4.38). Glucocorticoid therapy beyond 6 months is associated with a significantly greater risk of infections but not a significantly decreased risk of relapse.Keywords
This publication has 16 references indexed in Scilit:
- Improved outcome in 445 patients with Wegener's granulomatosis in a German vasculitis center over four decadesArthritis & Rheumatism, 2010
- Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody–associated vasculitis: A meta‐analysisArthritis Care & Research, 2010
- ANCA DiseaseJournal of the American Society of Nephrology, 2010
- Adverse effects of therapy for ANCA-associated vasculitisBest Practice & Research Clinical Rheumatology, 2009
- Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody–associated small‐vessel vasculitis: Comparison of two independent cohortsArthritis & Rheumatism, 2008
- Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosisRheumatology, 2007
- Predictors of Relapse and Treatment Resistance in Antineutrophil Cytoplasmic Antibody–Associated Small-Vessel VasculitisAnnals of Internal Medicine, 2005
- Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: A prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty‐five patientsArthritis Care & Research, 2003
- High rate of renal relapse in 71 patients with Wegener's granulomatosis under maintenance of remission with low‐dose methotrexateArthritis Care & Research, 2002
- Nomenclature of Systemic VasculitidesArthritis & Rheumatism, 1994